The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1418
Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved dimethyl fumarate (Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years for this indication.1

STANDARD TREATMENT — Interferon beta and glatiramer acetate are commonly used for first-line treatment of MS. Natalizumab and mitoxantrone are second-line parenteral drugs that have severe adverse effects. Oral drugs have only been available since 2010 and have generally been used as second-line agents.

MECHANISM OF ACTION — The mechanism of action of dimethyl fumarate in MS has not been established. It has been shown to activate an antioxidant response pathway (Nrf2) thought to be the primary cellular defense against oxidative stress.2

CLINICAL STUDIES — ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis
Article code: 1418b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian